In the BioHarmony Drug Report Database
Aprepitant
Cinvanti, Emend (aprepitant) is a small molecule pharmaceutical. Aprepitant was first approved as Cinvanti on 2003-03-26. It has been approved in Europe to treat neoplasms, postoperative nausea and vomiting, and vomiting. The pharmaceutical is active against substance-P receptor. Emend’s patents are valid until 2035-09-18 (FDA).
Trade Name
|
Emend |
|---|---|
Common Name
|
aprepitant |
ChEMBL ID
|
CHEMBL1471 |
Indication
|
neoplasms, postoperative nausea and vomiting, vomiting |
Drug Class
|
Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
Image (chem structure or protein)